<code id='FEDAF87640'></code><style id='FEDAF87640'></style>
    • <acronym id='FEDAF87640'></acronym>
      <center id='FEDAF87640'><center id='FEDAF87640'><tfoot id='FEDAF87640'></tfoot></center><abbr id='FEDAF87640'><dir id='FEDAF87640'><tfoot id='FEDAF87640'></tfoot><noframes id='FEDAF87640'>

    • <optgroup id='FEDAF87640'><strike id='FEDAF87640'><sup id='FEDAF87640'></sup></strike><code id='FEDAF87640'></code></optgroup>
        1. <b id='FEDAF87640'><label id='FEDAF87640'><select id='FEDAF87640'><dt id='FEDAF87640'><span id='FEDAF87640'></span></dt></select></label></b><u id='FEDAF87640'></u>
          <i id='FEDAF87640'><strike id='FEDAF87640'><tt id='FEDAF87640'><pre id='FEDAF87640'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:hotspot    Page View:8
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In